BioAffinity Technologies Current Ratio vs. EBITDA
| BIAFW Stock | USD 0.57 0.13 18.57% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 1.76736976 | Current Value 2 | Quarterly Volatility 2.68873498 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.3 | 0.3126 |
|
|
For BioAffinity Technologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioAffinity Technologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well bioAffinity Technologies Warrant utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioAffinity Technologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of bioAffinity Technologies Warrant over time as well as its relative position and ranking within its peers.
BioAffinity |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.744 | Quarterly Revenue Growth 120.474 | Return On Assets (0.70) | Return On Equity (1.52) |
The market value of BioAffinity Technologies is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies' value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies' market value can be influenced by many factors that don't directly affect BioAffinity Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioAffinity Technologies EBITDA vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioAffinity Technologies's current stock value. Our valuation model uses many indicators to compare BioAffinity Technologies value to that of its competitors to determine the firm's financial worth. bioAffinity Technologies Warrant is number one stock in current ratio category among its peers. It also is number one stock in ebitda category among its peers . At this time, BioAffinity Technologies' Current Ratio is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value BioAffinity Technologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.BioAffinity EBITDA vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
BioAffinity Technologies |
| = | 0.02 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
BioAffinity Technologies |
| = | (7.63 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
BioAffinity EBITDA Comparison
BioAffinity Technologies is currently under evaluation in ebitda category among its peers.
BioAffinity Technologies Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioAffinity Technologies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioAffinity Technologies will eventually generate negative long term returns. The profitability progress is the general direction of BioAffinity Technologies' change in net profit over the period of time. It can combine multiple indicators of BioAffinity Technologies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3.6 M | -3.8 M | |
| Operating Income | -8 M | -7.6 M | |
| Income Before Tax | -7.9 M | -8.3 M | |
| Total Other Income Expense Net | 57.2 K | 60.1 K | |
| Net Loss | -7.9 M | -8.3 M | |
| Income Tax Expense | 21 K | 22 K | |
| Net Interest Income | 47.3 K | 49.7 K | |
| Interest Income | 148.4 K | 155.8 K | |
| Net Loss | -7.2 M | -7.6 M | |
| Net Loss | (0.91) | (0.95) | |
| Income Quality | 0.76 | 0.42 | |
| Net Income Per E B T | 1.00 | 0.80 |
BioAffinity Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioAffinity Technologies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioAffinity Technologies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioAffinity Technologies' important profitability drivers and their relationship over time.
Use BioAffinity Technologies in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioAffinity Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioAffinity Technologies will appreciate offsetting losses from the drop in the long position's value.BioAffinity Technologies Pair Trading
bioAffinity Technologies Warrant Pair Trading Analysis
The ability to find closely correlated positions to BioAffinity Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioAffinity Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioAffinity Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling bioAffinity Technologies Warrant to buy it.
The correlation of BioAffinity Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioAffinity Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioAffinity Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioAffinity Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BioAffinity Technologies position
In addition to having BioAffinity Technologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Staples ETFs Thematic Idea Now
Consumer Staples ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Staples ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Staples ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.